& Methotrexate & 5-Florouracil
INDICATIONS: TREATMENT FOR STAGE I, II & III
(A&B) BREAST CANCERS
Combination chemotherapy with cyclophosphamide
(Cytoxan), methotrexate and 5-florouracil (5FU),
also called "CMF"
drugs have been approved by the FDA (Food and
Drug Administration) for the treatment of breast
600 mg/M2, Methotrexate 40 mg/M2, Florouracil 600
|DURATION AND TIMING:
Given once every 21 days for 6-8 treatments (5-7
decrease in blood cells, especially white
cells (neutropenia) but also red cells
(anemia) and/or platelets
possible nausea and vomiting (which may
be decreased or prevented with
medications); diarrhea; mouth sores;
severe hair loss; dry skin, nail thinning
cytoxan may cause irritation to the
kidneys or bladder.
cytoxan may cause damage to the ovaries
of premenopausal women. This may lead to
temporary or permanent infertility.
Patients may also develop an early
rare instances of irregular heart beats
or chest discomfort have been attributed
to 5FU (risk is increased in those with
underlying heart disease).
some patients complain of a decrease in
their ability to concentrate and/or
remember, which improves on completion of
some patients complain of taste changes
and/or lack of appetite.
1997 - TransMed Network